IMC Chicago’s Harmony Biosciences HRMY Stock Holding History

IMC Chicago’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Sell	10,000 -8,900	-47%	-$281K	﹤0.01%	5003
2026 Q1	$529K	Buy	18,900 +6,400	+51%	+$210K	﹤0.01%	3988
2025 Q4	$468K	Buy	+12,500	New	+$411K	﹤0.01%	3531

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IMC Chicago's HRMY Position: Q2 2026 in Review

IMC Chicago sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 11,765 shares — an estimated $371K sold.

IMC Chicago first reported a position in HRMY in Q1 2026 and held it in 1 quarter. The position peaked at $330K in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

IMC Chicago reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 11,765 Harmony Biosciences shares in Q2 2026, an estimated $371K.
IMC Chicago first reported a position in Harmony Biosciences in Q1 2026 and held it in 1 quarter.
IMC Chicago's Harmony Biosciences position peaked at $330K in Q1 2026.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.